These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 30522145)

  • 21. Introduction.
    Chilton R
    Am J Med; 2017 Jun; 130(6S):S1-S3. PubMed ID: 28526180
    [No Abstract]   [Full Text] [Related]  

  • 22. Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus.
    Heise T; Jordan J; Wanner C; Heer M; Macha S; Mattheus M; Lund SS; Woerle HJ; Broedl UC
    Clin Ther; 2016 Oct; 38(10):2248-2264.e5. PubMed ID: 27666126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents.
    Avranas K; Imprialos K; Stavropoulos K; Lales G; Manafis A; Skalkou A; Kihm L
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):94-103. PubMed ID: 29412124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of Sodium-Glucose Transporter-2 Inhibitors (SGLT-2i) in preventing chronic obstructive disease exacerbation in patients with diabetes and COPD: An electronic health database analysis.
    Gupta S; Mohta A; Lauinger A; Thameem D
    Heart Lung; 2024; 68():191-194. PubMed ID: 39029439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression.
    Permana H; Audi Yanto T; Ivan Hariyanto T
    Diabetes Res Clin Pract; 2023 Jan; 195():110205. PubMed ID: 36502891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes.
    Heise T; Jordan J; Wanner C; Heer M; Macha S; Mattheus M; Lund SS; Woerle HJ; Broedl UC
    Clin Ther; 2016 Oct; 38(10):2265-2276. PubMed ID: 27692976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Long-term Efficacy of Sodium Glucose Co-transporter 2 Inhibitor in Patients with Non-alcoholic Fatty Liver Disease.
    Yamashima M; Miyaaki H; Miuma S; Shibata H; Sasaki R; Haraguchi M; Fukushima M; Nakao K
    Intern Med; 2019; 58(14):1987-1992. PubMed ID: 31308341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of sodium-dependent glucose transporter inhibitors on glycated hemoglobin A1c after 24 weeks in patients with diabetes mellitus: A systematic review and meta-analysis.
    Chen MB; Wang H; Zheng QH; Xu HL; Cui WY
    Medicine (Baltimore); 2021 Jan; 100(1):e24101. PubMed ID: 33429775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prescription Trends for the Antidiabetic Agents Used to Treat Type 2 Diabetes Mellitus in Japan from 2012-2020: a Time-Series Analysis.
    Iketani R; Imai S
    Biol Pharm Bull; 2023; 46(4):592-598. PubMed ID: 37005303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Translating the statistical benefits of SGLT-2 inhibitors on cardio-renal outcomes into clinical practice.
    Ghosal S; Sinha B
    Expert Rev Clin Pharmacol; 2020 May; 13(5):545-551. PubMed ID: 32321327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors.
    Cersosimo E; Miles JM
    Curr Diabetes Rev; 2019; 15(4):314-327. PubMed ID: 30101716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of sodium-glucose cotransporter 2 inhibitors on the rate of decline in kidney function: A systematic review and meta-analysis.
    Duo Y; Gao J; Yuan T; Zhao W
    J Diabetes; 2023 Jan; 15(1):58-70. PubMed ID: 36610036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
    Grempler R; Thomas L; Eckhardt M; Himmelsbach F; Sauer A; Sharp DE; Bakker RA; Mark M; Klein T; Eickelmann P
    Diabetes Obes Metab; 2012 Jan; 14(1):83-90. PubMed ID: 21985634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased risk of erythrocytosis in men with type 2 diabetes treated with combined sodium-glucose cotransporter-2 inhibitor and testosterone replacement therapy.
    Gosmanov AR; Gemoets DE; Schumacher KA
    J Endocrinol Invest; 2024 Oct; 47(10):2615-2621. PubMed ID: 38536657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of atenolol on aldosterone/renin ratio calculated by both plasma Renin activity and direct Renin concentration in healthy male volunteers.
    Ahmed AH; Gordon RD; Taylor P; Ward G; Pimenta E; Stowasser M
    J Clin Endocrinol Metab; 2010 Jul; 95(7):3201-6. PubMed ID: 20427490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL.
    Cavender MA; Norhammar A; Birkeland KI; Jørgensen ME; Wilding JP; Khunti K; Fu AZ; Bodegård J; Blak BT; Wittbrodt E; Thuresson M; Fenici P; Hammar N; Kosiborod M;
    J Am Coll Cardiol; 2018 Jun; 71(22):2497-2506. PubMed ID: 29852973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cross-sectional study of the effects of β-blocker therapy on the interpretation of the aldosterone/renin ratio: can dosing regimen predict effect?
    Griffin TP; Browne GA; Wall D; Dennedy MC; OʼShea PM
    J Hypertens; 2016 Feb; 34(2):307-15. PubMed ID: 26867057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prescription Patterns of Novel Antihyperglycemic Medications.
    Ali AS; Khan M; Ortega D; Jaffery S; Lamerato LE; Budzynska K
    J Am Board Fam Med; 2022; 35(2):255-264. PubMed ID: 35379713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials.
    Singh AK; Singh R
    Diabetes Res Clin Pract; 2021 Feb; 172():108648. PubMed ID: 33421444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.
    Zhou B; Shi Y; Fu R; Ni H; Gu L; Si Y; Zhang M; Jiang K; Shen J; Li X; Sun X
    Front Endocrinol (Lausanne); 2022; 13():907340. PubMed ID: 35692406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.